Desperate hope: one patient gets custom immune cells for rare cancer
NCT ID NCT06789081
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a one-of-a-kind cell therapy called GCAR1 in a single patient with advanced alveolar soft part sarcoma, a rare cancer that has spread. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells that carry a specific protein (GPNMB). The main goal is to see if the tumor shrinks after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GCAR1 (a personalized cell therapy made from the patient's own immune cells, engineered to target cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for alveolar soft part sarcoma, a rare cancer with few alternatives.
- What could go wrong
- This is an extremely early trial with only one patient, so results may not apply to others. The therapy is experimental and may not shrink the tumor or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- New combo therapy aims to shrink sarcomas
- New drug cocktail shows promise for rare sarcoma
- New pill shows promise in slowing rare Cancer's growth
- New hope for rare sarcoma patients: AL3818 drug trial underway
- New combo targets sarcoma in limbs